Arcus Biosciences Ownership | Who Owns Arcus Biosciences?
Arcus Biosciences Ownership Summary
Arcus Biosciences is owned by 98.69% institutional investors, 5.18% insiders. Gilead sciences is the largest institutional shareholder, holding 32.89% of RCUS shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 3.81% of its assets in Arcus Biosciences shares.
RCUS Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Arcus Biosciences | 98.69% | 5.18% | -3.87% |
| Sector | Healthcare Stocks | 279.19% | 10.62% | -189.81% |
| Industry | Biotech Stocks | 63.96% | 10.74% | 25.30% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Gilead sciences | 30.06M | 32.89% | $447.61M |
| Blackrock | 9.76M | 11.33% | $148.69M |
| Blackrock funding, inc. /de | 9.69M | 10.61% | $144.35M |
| Vanguard group | 5.39M | 5.90% | $80.25M |
| Fmr | 4.05M | 4.43% | $60.34M |
| Woodline partners lp | 3.52M | 3.86% | $52.47M |
| State street | 2.99M | 3.28% | $44.58M |
| Point72 asset management | 2.00M | 2.18% | $29.72M |
| Invus financial advisors | 1.61M | 1.87% | $24.55M |
| Dimensional fund advisors lp | 1.70M | 1.86% | $25.35M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Gilead sciences | 30.06M | 28.86% | $447.61M |
| Invus financial advisors | 1.61M | 27.51% | $24.55M |
| Decheng capital | 808.79K | 2.58% | $12.04M |
| Parkman healthcare partners | 1.27M | 2.53% | $18.97M |
| Boxer capital | 1.60M | 1.28% | $24.40M |
| Siren | 1.61M | 1.06% | $24.00M |
| Dafna capital management | 254.22K | 0.96% | $3.79M |
| Ikarian capital | 378.36K | 0.77% | $5.63M |
| Sectoral asset management | 69.55K | 0.69% | $1.04M |
| Woodline partners lp | 3.52M | 0.35% | $52.47M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Gilead sciences | 30.06M | 28.86% | 30.06M |
| Millennium management | 924.37K | 0.01% | 679.27K |
| Bnp paribas asset management | 1.52M | 0.06% | 590.74K |
| Parkman healthcare partners | 1.27M | 2.53% | 248.03K |
| Ameriprise financial | 1.55M | 0.01% | 228.32K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Alliancebernstein | 72.51K | 0.00% | -1.23M |
| Braidwell lp | - | - | -802.10K |
| Schonfeld strategic advisors | 135.00K | 0.01% | -538.84K |
| Adage capital partners gp | - | - | -443.00K |
| Point72 asset management | 2.00M | 0.07% | -440.79K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Gilead sciences | 30.06M | 28.86% | 30.06M | $447.61M |
| Raymond james financial | 35.66K | 0.00% | 35.66K | $531.01K |
| Norges bank | 34.04K | 0.00% | 34.04K | $506.92K |
| Clarivest asset management | 17.09K | 0.03% | 17.09K | $260.31K |
| Peak6 | 10.00K | 0.00% | 10.00K | $148.90K |
Sold Out
| Holder | Change |
|---|---|
| Dinuzzo private wealth | -1.00 |
| Farther finance advisors | -1.00 |
| Sjs investment consulting | -5.00 |
| Massmutual trust co fsb/adv | -7.00 |
| Jfs wealth advisors | -7.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | 187 | -3.11% | 97,113,724 | 15.75% | 98 | 1.17% | 126 | 44.83% | 30 | -55.22% |
| Dec 31, 2024 | 119 | -37.70% | 59,398,024 | 11.54% | 64 | 1.91% | 52 | -40.91% | 38 | -46.48% |
| Sep 30, 2024 | 190 | -4.52% | 53,251,839 | 2.50% | 58 | 1.79% | 89 | -16.82% | 70 | 16.67% |
| Jun 30, 2024 | 196 | 8.89% | 51,943,543 | -1.54% | 60 | 1.19% | 106 | 27.71% | 59 | 5.36% |
| Mar 31, 2024 | 180 | -8.16% | 52,758,521 | -0.09% | 71 | 1.42% | 83 | -5.68% | 56 | -17.65% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4.03M | 3.81% | -2.52K |
| Vanguard Total Stock Mkt Idx Inv | 2.15M | 2.04% | - |
| Vanguard US Total Market Shares ETF | 1.62M | 1.53% | - |
| iShares Russell 2000 ETF | 1.39M | 1.32% | 681.00 |
| Fidelity Select Biotechnology | 1.39M | 1.31% | -168.60K |
| SPDR® S&P Biotech ETF | 1.27M | 1.20% | 1.64K |
| Vanguard Institutional Extnd Mkt Idx Tr | 1.06M | 1.00% | 2.08K |
| Fidelity Select Health Care | 949.76K | 0.90% | - |
| Fidelity Select Pharmaceuticals Port | 915.02K | 0.86% | -71.50K |
| CT (Lux) American Smaller Com 9U USD | 906.88K | 0.86% | 55.03K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Feb 27, 2025 | KANEKO YASUNORI | - | Buy | $201.20K |
| Feb 27, 2025 | ROSEN TERRY J | Chief Executive Officer | Buy | $201.47K |
| Feb 18, 2025 | GILEAD SCIENCES, INC. | - | Buy | $15.00M |
| Dec 31, 2024 | Goeltz II Robert C. | Chief Financial Officer | Sell | $53.91K |
| Dec 02, 2024 | Azoy Alexander | Chief Accounting Officer | Sell | $3.08K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q2 | - | - |
| 2025 Q1 | 3 | - |
| 2024 Q4 | - | 2 |
| 2024 Q3 | - | 1 |
| 2024 Q2 | - | - |
RCUS Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools